568 related articles for article (PubMed ID: 15547685)
1. Role of histone deacetylase inhibitors in the treatment of cancer (Review).
Mei S; Ho AD; Mahlknecht U
Int J Oncol; 2004 Dec; 25(6):1509-19. PubMed ID: 15547685
[TBL] [Abstract][Full Text] [Related]
2. HDAC inhibitors for the treatment of cancer.
Secrist JP; Zhou X; Richon VM
Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
[TBL] [Abstract][Full Text] [Related]
3. Development of histone deacetylase inhibitors for cancer treatment.
Marchion D; Münster P
Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
[TBL] [Abstract][Full Text] [Related]
4. Acetylation of proteins as novel target for antitumor therapy: review article.
Di Gennaro E; Bruzzese F; Caraglia M; Abruzzese A; Budillon A
Amino Acids; 2004 Jul; 26(4):435-41. PubMed ID: 15290351
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R
Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297
[TBL] [Abstract][Full Text] [Related]
6. Prospects: histone deacetylase inhibitors.
Dokmanovic M; Marks PA
J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors.
Marks PA; Richon VM; Miller T; Kelly WK
Adv Cancer Res; 2004; 91():137-68. PubMed ID: 15327890
[TBL] [Abstract][Full Text] [Related]
8. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma.
Lai JP; Yu C; Moser CD; Aderca I; Han T; Garvey TD; Murphy LM; Garrity-Park MM; Shridhar V; Adjei AA; Roberts LR
Gastroenterology; 2006 Jun; 130(7):2130-44. PubMed ID: 16762634
[TBL] [Abstract][Full Text] [Related]
9. [Histone-deacetylases inhibitors: from TSA to SAHA].
Peixoto P; Lansiaux A
Bull Cancer; 2006 Jan; 93(1):27-36. PubMed ID: 16455503
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors: biology and mechanism of action.
Mehnert JM; Kelly WK
Cancer J; 2007; 13(1):23-9. PubMed ID: 17464243
[TBL] [Abstract][Full Text] [Related]
11. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors in cancer therapy.
Lane AA; Chabner BA
J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
[TBL] [Abstract][Full Text] [Related]
13. Anticancer activities of histone deacetylase inhibitors.
Bolden JE; Peart MJ; Johnstone RW
Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
[TBL] [Abstract][Full Text] [Related]
14. Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid.
Kelly WK; Marks PA
Nat Clin Pract Oncol; 2005 Mar; 2(3):150-7. PubMed ID: 16264908
[TBL] [Abstract][Full Text] [Related]
15. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.
Yoshida M; Shimazu T; Matsuyama A
Prog Cell Cycle Res; 2003; 5():269-78. PubMed ID: 14593721
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.
Graham C; Tucker C; Creech J; Favours E; Billups CA; Liu T; Fouladi M; Freeman BB; Stewart CF; Houghton PJ
Clin Cancer Res; 2006 Jan; 12(1):223-34. PubMed ID: 16397046
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylation as a target for radiosensitization.
Cerna D; Camphausen K; Tofilon PJ
Curr Top Dev Biol; 2006; 73():173-204. PubMed ID: 16782459
[TBL] [Abstract][Full Text] [Related]
18. [Assay for inhibitory activity of histone deacetylase].
Yoshida M
Gan To Kagaku Ryoho; 2004 Apr; 31(4):507-11. PubMed ID: 15114691
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors in myelodysplastic syndrome.
Bhalla K; List A
Best Pract Res Clin Haematol; 2004 Dec; 17(4):595-611. PubMed ID: 15494297
[TBL] [Abstract][Full Text] [Related]
20. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.
Johnstone RW
Nat Rev Drug Discov; 2002 Apr; 1(4):287-99. PubMed ID: 12120280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
